???global.info.a_carregar???
António Araújo is Head of the Department of Medical Oncology at Centro Hospitalar Universitário do Porto, and Full Professor at School of Medicine and Biomedical Sciences - ICBAS and at Dental Medical Faculty, University of Porto. Since January.2023 he is Head of the Integrated Master Degree in Medicine at School of Medicine and Biomedical Sciences – ICBAS, University of Porto. He is member of the Portuguese National Council for Oncology, since 2013, and member of the Scientific Committee of the Portuguese National Cancer Registry since 2019. He was member of the International Association for Study of Lung Cancer Ethic Committee for the term 2015-2019, and is member of its Educational Committee since 2019. He was member of the Executive Board of the Portuguese Lung Cancer Study Group, from 2006 to 2012. He is a founding member of REDICAP - Red IberoAmericana de Cancer de Pulmón, founded on 12th February 2021, and which includes oncologic researchers from Spain, Colombia, Argentina, Peru and Portugal. He was President of the Executive Board of the Northern Regional Council of the Portuguese Medical Association from 2017-2022. Professor Araújo has authored or contributed to more than 120 scientific papers and book chapters. He is a full member of ESMO, ASCO, IASLC, Portuguese Society of Oncology and Portuguese Society of Pulmonology. In 2022, he was distinguished with the Municipal Medal of Merit – Gold Grade, by the city of Porto.
Ler resumo completo ↓
Identificação

Identificação pessoal

Nome completo
António Manuel Ferreira Araújo

Nomes de citação

  • Araújo, António

Identificadores de autor

Ciência ID
0715-EC47-869F
ORCID iD
0000-0002-7267-3584
Scopus Author Id
16229446200

Telefones

Telemóvel
  • 917258865 (Profissional)

Domínios de atuação

  • Ciências Médicas e da Saúde - Medicina Clínica - Oncologia

Idiomas

Idioma Conversação Leitura Escrita Compreensão Peer-review
Inglês Utilizador proficiente (C1) Utilizador independente (B2) Utilizador independente (B2) Utilizador proficiente (C1) Utilizador proficiente (C1)
Francês Utilizador proficiente (C1) Utilizador independente (B2) Utilizador independente (B2) Utilizador proficiente (C1) Utilizador proficiente (C1)
Espanhol; Castelhano Utilizador proficiente (C1) Utilizador independente (B2) Utilizador independente (B1) Utilizador proficiente (C2) Utilizador proficiente (C1)
Português (Idioma materno)
Formação
Grau Classificação
1996/02/01 - 2010/12/14
Concluído
 Doutoramento em Ciências Médicas (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
"From Selection of Patients with Non-Small-Cell Lung Cancer to the Cost of Treatment in Portugal: Evaluation of Second and Third Lines Treatment " (TESE/DISSERTAÇÃO)
 Aprovado com Distinção
2010
Concluído
 Ciências Médicas (Doutoramento)
Especialização em Não Aplicável
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
1981/09/01 - 1987/07/30
Concluído
 Medicina (Licenciatura)
Universidade do Porto Faculdade de Medicina, Portugal
Percurso profissional

Docência no Ensino Superior

Categoria Profissional
Instituição de acolhimento 		Empregador
2020/09/01 - Atual Professor Catedrático Convidado (Docente Universitário) Universidade do Porto Faculdade de Medicina Dentária, Portugal
Universidade do Porto Faculdade de Medicina Dentária, Portugal
2017/09/01 - Atual Professor Catedrático Convidado (Docente Universitário) Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017 - 2019 Professor Catedrático Convidado (Docente Universitário) Universidade do Porto, Portugal
2016 - 2017 Professor Auxiliar Convidado (Docente Universitário) Universidade do Porto, Portugal
2015 - 2016 Professor Auxiliar (Docente Universitário) Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Cargos e Funções

Categoria Profissional
Instituição de acolhimento 		Empregador
2014/03/15 - Atual Director de Unidade Orgânica Centro Hospitalar Universitário do Porto EPE, Portugal

Outros

Categoria Profissional
Instituição de acolhimento 		Empregador
2023/01/02 - Atual Director do Mestrado Integrado em Medicina Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
Projetos

Projeto

Designação Financiadores
2021/01/01 - 2025/12/31 Laboratório para a Investigação Integrativa e translacional em Saúde Populacional
LA/P/0064/2020
Universidade do Porto Instituto de Saúde Pública, Portugal
 Fundação para a Ciência e a Tecnologia
Em curso
2019/01/01 - 2019/12/31 Unidade Multidisciplinar de Investigação Biomédica - UMIB
UID/Multi/00215/2019
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Universidade do Porto Unidade Multidisciplinar de Investigação Biomédica, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
2011/01/01 - 2013/12/31 Projecto Estratégico - UI 776 - 2011-2012
PEst-OE/SAU/UI0776/2011
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
 Fundação para a Ciência e a Tecnologia
Concluído
2010/05/01 - 2013/10/31 Desenvolvimento e validação de um modelo farmacocinético/farmacodinâmico para a individualização das doses de carboplatina e gemcitabina a administrar em doentes idosos com carcinoma de pulmão de não pequenas células avançado
PTDC/SAU-FCF/104448/2008
Universidade do Porto Instituto de Ciências Tecnologias e Agroambiente, Portugal

Rede de Química e Tecnologia Laboratório Associado para a Química Verde, Portugal

Universidade do Porto Faculdade de Farmácia, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
Produções

Publicações

Artigo em revista
  1. A. Barroso; F. Estevinho; V. Hespanhol; E. Teixeira; J. Ramalho-Carvalho; A. Araújo. "Management of infusion-related reactions in cancer therapy: strategies and challenges". ESMO Open (2024): https://doi.org/10.1016/j.esmoop.2024.102922.
    10.1016/j.esmoop.2024.102922
  2. João Queirós Coelho; Raquel Romão; Maria João Sousa; Sérgio Xavier Azevedo; Paula Fidalgo; António Araújo. "Vitiligo-like Lesions as a Predictor of Response to Immunotherapy in Non-Small Cell Lung Cancer: Comprehensive Review and Case Series from a University Center". Current Oncology (2024): https://doi.org/10.3390/curroncol31020083.
    10.3390/curroncol31020083
  3. Andriani Charpidou; Grigorios Gerotziafas; Sanjay Popat; Antonio Araujo; Arnaud Scherpereel; Hans-Georg Kopp; Paolo Bironzo; et al. "Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade". Cancers (2024): https://doi.org/10.3390/cancers16020450.
    10.3390/cancers16020450
  4. Maria João Ramos; Ana Sofia Mendes; Raquel Romão; Joana Febra; António Araújo. "Immunotherapy in Elderly Patients—Single-Center Experience". Cancers (2023): https://doi.org/10.3390/cancers16010145.
    10.3390/cancers16010145
  5. Urska Janzic; Walid Shalata; Katarzyna Szymczak; Rafal Dziadziuszko; Marko Jakopovic; Giannis Mountzios; Adam Pluzanski; et al. "Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations". International Journal of Molecular Sciences (2023): https://doi.org/10.3390/ijms241612840.
    10.3390/ijms241612840
  6. Ridhi Ranchor; Nuno Pereira; Ana R. Medeiros; Manuel Magalhães; Aníbal Marinho; António Araújo. "Characteristics and Outcomes of COVID-19 Cancer Patients Admitted to a Portuguese Intensive Care Unit: A Case-Control Study". Cancers (2023): https://doi.org/10.3390/cancers15123264.
    10.3390/cancers15123264
  7. Teresa Guerreiro; Alexandra Mayer; Pedro Aguiar; António Araújo; Carla Nunes. "The Effect of Timeliness of Care on Lung Cancer Survival – A Population-Based Approach". Annals of Global Health (2023): https://doi.org/10.5334/aogh.3845.
    10.5334/aogh.3845
  8. Raquel Romão; Ana S. Mendes; Ridhi Ranchor; Maria João Ramos; João Coelho; Rita Carrilho Pichel; Sérgio Xavier Azevedo; Paula Fidalgo; António Araújo. "Impact of Immune-Related Adverse Events on Immune Checkpoint Inhibitors Treated Cancer Patients’ Survival: Single Center Experience and Literature Review". Cancers (2023): https://doi.org/10.3390/cancers15030888.
    10.3390/cancers15030888
  9. António Araújo; Nuno Tavares; Ana Luísa Faria; Rosa Gomes; Joana Carvalho Mendonça; Bárbara Parente; Andreia Capela; Fernando Barata; Ana Macedo. "Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal". Current Oncology (2023): https://doi.org/10.3390/curroncol30020117.
    10.3390/curroncol30020117
  10. A. Araújo; A. Barroso; B. Parente; C. Travancinha; E. Teixeira; F. Martelo; G. Fernandes; et al. "Unresectable stage III non-small cell lung cancer: Insights from a Portuguese expert panel". Pulmonology (2023): https://doi.org/10.1016/j.pulmoe.2022.11.008.
    10.1016/j.pulmoe.2022.11.008
  11. Mendes, Ana Sofia; Romao, Raquel; Febra, Joana; Azevedo, Sergio Xavier; Fidalgo, Paula; Araujo, Antonio. "Chemotherapy: A partnership with immunotherapy in non-small cell lung cancer". Thoracic Cancer (2023): https://publons.com/wos-op/publon/63048710/.
    10.1111/1759-7714.14779
  12. Liz-Pimenta, Joana; Tavares, Valeria; Neto, Beatriz Vieira; Santos, Joana M. O.; Guedes, Catarina Brandao; Araujo, Antonio; Khorana, Alok A.; Medeiros, Rui. "Thrombosis and cachexia in cancer: Two partners in crime?". Critical Reviews in Oncology/Hematology (2023): https://publons.com/wos-op/publon/60598587/.
    10.1016/J.CRITREVONC.2023.103989
  13. Rita Carrilho Pichel; Alexandra Araújo; Vital Da Silva Domingues; Jorge Nunes Santos; Elga Freire; Ana Sofia Mendes; Raquel Romão; António Araújo. "Best Supportive Care of the Patient with Oesophageal Cancer". Cancers (2022): https://doi.org/10.3390/cancers14246268.
    10.3390/cancers14246268
  14. Raquel Romão; Hugo Miranda; Isa Peixoto; Ana Mendes; Sérgio Azevedo; Paula Fidalgo; António Araújo. "Valor prognóstico do rácio neutrófilos/ linfócitos em doentes com carcinoma do pulmão não pequenas células tratados com imunoterapia em contexto paliativo". Revista do Grupo de Estudos do Cancro do Pulmão (2022): https://doi.org/10.32932/gecp.2022.09.023.
    10.32932/gecp.2022.09.023
  15. Abed Agbarya; Walid Shalata; alfredo addeo; Andriani Charpidou; Kristof Cuppens; Odd Terje Brustugun; Mirjana Rajer; et al. "Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment". Journal of Clinical Medicine (2022): https://www.mdpi.com/2077-0383/11/6/1738.
    10.3390/jcm11061738
  16. "Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience". Annals of Hepatology (2021): 100561-100561. http://dx.doi.org/10.1016/j.aohep.2021.100561.
    10.1016/j.aohep.2021.100561
  17. T. Guerreiro; G. Forjaz; L. Antunes; J. Bastos; A. Mayer; P. Aguiar; A. Araújo; C. Nunes. "Lung cancer survival and sex-specific patterns in Portugal: A population-based analysis". Pulmonology (2021): https://doi.org/10.1016/j.pulmoe.2021.09.001.
    10.1016/j.pulmoe.2021.09.001
  18. Carolina Fleming; Paula Fidalgo; Hugo Miranda; Raquel Romão; António Araújo; José Vizcaíno. "Análise descritiva da expressão de PD­-L1 em biopsias de carcinoma de não pequenas células do pulmão: experiência de dois anos em Hospital terciário". Revista do Grupo de Estudos do Cancro do Pulmão (2021): https://doi.org/10.32932/gecp.2021.07.014.
    10.32932/gecp.2021.07.014
  19. Araújo, António. "T790M-EGFR mutation frequency in advanced NSCLC patients on progression from a previous TKI therapy: results from a Portuguese study". Pulmonology (2021): http://dx.doi.org/10.1016/j.pulmoe.2021.01.007.
    10.1016/j.pulmoe.2021.01.007
  20. Ana Silva; Francisco Gomes; Sofia S. Pereira; Mariana P. Monteiro; António Araújo; Gil Faria. "Visceral obesity is associated with lower stage colon tumors in males without survival advantage". Surgical Oncology 37 (2021): 101606-101606. https://doi.org/10.1016/j.suronc.2021.101606.
    10.1016/j.suronc.2021.101606
  21. Araújo, António. "Cancer-Related Venous Thromboembolism: From Pathogenesis to Risk Assessment.". Seminars in thrombosis and hemostasis (2021): https://doi.org/10.1055/s-0040-1718926.
    10.1055/s-0040-1718926
  22. Silva, Ana; Pereira, Sofia S.; Monteiro, Mariana P.; Araujo, Antonio; Faria, Gil. "EFFECT OF METABOLIC SYNDROME AND INDIVIDUAL COMPONENTS ON COLON CANCER CHARACTERISTICS AND PROGNOSIS". Frontiers in Oncology (2021): https://publons.com/wos-op/publon/30404843/.
    10.3389/FONC.2021.631257
  23. António Araújo; Filipa Machado Vaz; Manuela Duarte; Carla Rocha; Eugénia Rosendo. "A Perspective About the Construction of the “Hospital de Campanha Porto.”". Acta Médica Portuguesa 33 13 (2020): https://doi.org/10.20344/amp.14702.
    10.20344/amp.14702
  24. João Poço Gonçalves; Dalila Veiga; António Araújo. "Chronic pain, functionality and quality of life in cancer survivors". British Journal of Pain (2020): 204946372097273-204946372097273. https://doi.org/10.1177%2F2049463720972730.
    10.1177/2049463720972730
  25. TERESA GUERREIRO; LUIS ANTUNES; JOANA BASTOS; ALEXANDRA MAYER; GONCALO FORJAZ; ANTÓNIO ARAUJO; CARLA NUNES. "Lung Cancer: A Nationwide Study to Characterize Sex Differences, Incidence, and Spatial Patterns in Portugal". In Vivo 34 5 (2020): 2711-2719. https://doi.org/10.21873%2Finvivo.12092.
    10.21873/invivo.12092
  26. Ana Silva; Gil Faria; António Araújo; Mariana P. Monteiro. "Impact of adiposity on staging and prognosis of colorectal cancer". Critical Reviews in Oncology/Hematology 145 (2020): 102857-102857. https://doi.org/10.1016%2Fj.critrevonc.2019.102857.
    10.1016/j.critrevonc.2019.102857
  27. Araújo, António. "Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC)". Pulmonology 26 1 (2020): 10-17. http://dx.doi.org/10.1016/j.pulmoe.2019.06.001.
    10.1016/j.pulmoe.2019.06.001
  28. Francisco Ribeiro-Mourão; António Araújo; Carlos Cortes; Tiago Villanueva; João Carlos Ribeiro. "Is There a Surplus of Non-Specialist Physicians in Portugal or Just Poor Human Resources Planning?". Acta Médica Portuguesa 31 11 (2018): 609-609. https://doi.org/10.20344%2Famp.11273.
    10.20344/amp.11273
  29. Filipe Coutinho; Miguel Horta; Estrela Rocha; Carlos Vasconcelos; António Araújo. "Merkel cell carcinoma and the challenge in its approach: a review based on a clinical context of immunosuppression". Porto Biomedical Journal 3 1 (2018): e11-e11. https://doi.org/10.1016%2Fj.pbj.0000000000000011.
    10.1016/j.pbj.0000000000000011
  30. Ana Luísa Coelho; Mónica Patrícia Gomes; Raquel Jorge Catarino; Christian Rolfo; Rui Manuel Medeiros; António Manuel Araújo. "CSF-1 and Ang-2 serum levels — prognostic and diagnostic partners in non-small cell lung cancer". ESMO Open 3 5 (2018): e000349-e000349. https://doi.org/10.1136/esmoopen-2018-000349.
    10.1136/esmoopen-2018-000349
  31. Joaquim A; Custódio S; Savva-Bordalo J; Chacim S; Carvalhais I; Lombo L; Lopes H; Araújo A; Gomes R. "Burnout and occupational stress in the medical residents of Oncology, Haematology and Radiotherapy: a prevalence and predictors study in Portugal.". Psychology, health & medicine (2018): http://europepmc.org/abstract/med/28661187.
    10.1080/13548506.2017.1344256
  32. Marta Rocha; João Correia de Sousa; Marta Salgado; António Araújo; Isabel Pedroto. "Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor". GE - Portuguese Journal of Gastroenterology 26 4 (2018): 268-274. https://doi.org/10.1159%2F000494569.
    10.1159/000494569
  33. Pereira, Joao Luis; Gomes, Monica; Teixeira, Ana Luisa; Coelho, Ana; Rolfo, Christian; Araujo, Antonio. "Potential and importance of metalloproteinases and interleukins in inflammation and metastasization in non-small cell lung cancer". Translational Cancer Research (2018): https://publons.com/wos-op/publon/20962658/.
    10.21037/TCR.2018.05.16
  34. Santos MD; Silva C; Rocha A; Nogueira C; Castro-Poças F; Araujo A; Matos E; et al. "Predictive clinical model of tumor response after chemoradiation in rectal cancer.". Oncotarget (2017): http://europepmc.org/abstract/med/28778099.
    10.18632/oncotarget.19651
  35. Coelho AL; Gomes MP; Catarino RJ; Rolfo C; Lopes AM; Medeiros RM; Araújo AM. "Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?". Oncotarget (2017): http://europepmc.org/abstract/med/26950275.
    10.18632/oncotarget.7794
  36. Porta R; Borea R; Coelho A; Khan S; Araújo A; Reclusa P; Franchina T; et al. "FGFR a promising druggable target in cancer: Molecular biology and new drugs.". Critical reviews in oncology/hematology (2017): http://europepmc.org/abstract/med/28427515.
    10.1016/j.critrevonc.2017.02.018
  37. Santos MD; Silva C; Rocha A; Nogueira C; Castro-Poças F; Araujo A; Matos E; et al. "Prognostic and Therapeutic Potential Implications of Genetic Variability in Prostaglandin E2 Pathway Genes in Rectal Cancer.". Anticancer research (2017): http://europepmc.org/abstract/med/28011504.
    10.21873/anticanres.11319
  38. Rolfo C; Caglevic C; Santarpia M; Araujo A; Giovannetti E; Gallardo CD; Pauwels P; Mahave M. "Immunotherapy in NSCLC: A Promising and Revolutionary Weapon.". Advances in experimental medicine and biology (2017): http://europepmc.org/abstract/med/28321814.
    10.1007/978-3-319-53156-4_5
  39. De Mello, Ramon Andrade; Luis, Michael; Araujo, Antonio; Reis, Rui Manuel; Hespanhol, Venceslau. "The Role of Angiogenesis in Non-small Cell Lung Cancer Tumor Behavior". Biochemical Basis and Therapeutic Implications of Angiogenesis, Edition (2017): https://publons.com/wos-op/publon/15199732/.
    10.1007/978-3-319-61115-0_10
  40. Reclusa P; Sirera R; Araujo A; Giallombardo M; Valentino A; Sorber L; Bazo IG; Pauwels P; Rolfo C. "Exosomes genetic cargo in lung cancer: a truly Pandora's box.". Translational lung cancer research (2016): http://europepmc.org/abstract/med/27826529.
    10.21037/tlcr.2016.10.06
  41. Tan DS; Araújo A; Zhang J; Signorovitch J; Zhou ZY; Cai X; Liu G. "Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.". Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2016): http://europepmc.org/abstract/med/27288979.
    10.1016/j.jtho.2016.05.029
  42. Taverna S; Giallombardo M; Gil-Bazo I; Carreca AP; Castiglia M; Chacártegui J; Araujo A; et al. "Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice.". Oncotarget (2016): http://europepmc.org/abstract/med/26919248.
    10.18632/oncotarget.7638
  43. Goeree R; Villeneuve J; Goeree J; Penrod JR; Orsini L; Tahami Monfared AA. "Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes.". Journal of medical economics (2016): http://europepmc.org/abstract/med/26850122.
    10.3111/13696998.2016.1151432
  44. Paiva C; Garcia J; Silva C; Araújo A; Santos MD. "Single Jejunum Metastasis from Breast Cancer Arising Twelve Years after the Initial Treatment.". Case reports in oncological medicine (2016): http://europepmc.org/abstract/med/27781130.
    10.1155/2016/8594652
  45. Castro, Ana Filipa Martins Ferreira; Febra, Joana; Coelho, Andreia Machado; Rocha, Mariana; Lopes, Silvia; Joaquim, Ana; Gouveia, Helena; et al. "Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal in 2012". Journal of Clinical Oncology (2016): https://publons.com/wos-op/publon/20962663/.
    10.1200/JCO.2016.34.15_SUPPL.E17524
  46. "Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal". Annals of Oncology (2016): https://publons.com/wos-op/publon/20962662/.
    10.1093/ANNONC/MDW376.40
  47. "Validation of Portuguese version of the MD Anderson Symptom Inventory (MDASI) for patients with head and neck cancer.". Journal of Clinical Oncology (2016): https://publons.com/wos-op/publon/20962664/.
    10.1200/JCO.2016.34.15_SUPPL.E18225
  48. Gomes M; Coelho A; Araújo A; Azevedo A; Teixeira AL; Catarino R; Medeiros R. "IL-6 polymorphism in non-small cell lung cancer: a prognostic value?". Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (2015): http://europepmc.org/abstract/med/25566963.
    10.1007/s13277-014-3006-6
  49. Coelho AL; Araújo AM; Gomes MP; Catarino RJ; Andrade EB; Lopes AM; Medeiros RM. "Combined Ang-2 and VEGF serum levels: holding hands as a new integral biomarker in non-small-cell lung cancers.". Future oncology (London, England) (2015): http://europepmc.org/abstract/med/26562248.
    10.2217/fon.15.207
  50. Tan, Daniel Shao-Weng; Araujo, Antonio; Zhang, Jie; Signorovitch, James E.; Zhou, Zheng-Yi; Cai, Xiaopeng; Liu, Geoffrey. "Comparative efficacy of ceritinib and crizotinib in previously treated crizotinib-naive anaplastic lymphoma kinase-positive (ALK plus ) advanced or metastatic non-small cell lung cancer (NSCLC): An adjusted indirect comparison". Journal of Clinical Oncology (2015): https://publons.com/wos-op/publon/20962665/.
  51. Gomes, M.; Coelho, A. L.; Araujo, A.; Teixeira, A. L.; Medeiros, R.. "Can be MMP-7-153C/T a possible marker for distant metastasis risk in non small cell lung cancer?". European Journal of Cancer (2015): https://publons.com/wos-op/publon/14118920/.
    10.1016/S0959-8049(16)30162-9
  52. Lima A; Seabra V; Martins S; Coelho A; Araújo A; Medeiros R. "Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.". Molecular biology reports (2014): http://europepmc.org/abstract/med/24554028.
    10.1007/s11033-014-3197-3
  53. Peixoto V; Faria AL; Gonçalves M; Macedo J; Rego S; Macías E; Magano A; Loureiro M; Araújo A. "Evolution of costs of cancer drugs in a Portuguese hospital.". World journal of clinical oncology (2014): http://europepmc.org/abstract/med/24829864.
    10.5306/wjco.v5.i2.164
  54. Butts C; Socinski MA; Mitchell PL; Thatcher N; Havel L; Krzakowski M; Nawrocki S; et al. "Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.". The Lancet. Oncology (2014): http://europepmc.org/abstract/med/24331154.
    10.1016/s1470-2045(13)70510-2
  55. Gomes M; Teixeira AL; Coelho A; Araújo A; Medeiros R. "The role of inflammation in lung cancer.". Advances in experimental medicine and biology (2014): http://europepmc.org/abstract/med/24818717.
    10.1007/978-3-0348-0837-8_1
  56. Coelho AL; Araújo A; Gomes M; Catarino R; Marques A; Medeiros R. "Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected].". PloS one (2014): http://europepmc.org/abstract/med/24587185.
    10.1371/journal.pone.0090009
  57. de Mello RA; Madureira P; Carvalho LS; Araújo A; O'Brien M; Popat S. "EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.". (2013): http://europepmc.org/abstract/med/24192124.
    10.2217/pgs.13.177
  58. Marques I; Araújo A; de Mello RA. "Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives.". World journal of gastroenterology (2013): http://europepmc.org/abstract/med/24307789.
    10.3748/wjg.v19.i44.7955
  59. De Mello RA; Araújo A. "Anaplastic lymphoma kinase gene rearrangement and non-small cell lung cancer management: a step forward in personalized therapy.". (2013): http://europepmc.org/abstract/med/23778423.
    10.6061/clinics/2013(05)24
  60. Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; et al. "Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.". (2013): http://europepmc.org/abstract/med/23594786.
    10.1016/S1470-2045(13)70102-5
  61. De Mello RA; Araújo A; Hespanhol V; Reis RM. "Loci identified through genome-wide association studies and lung cancer risk: is there anything more?". (2013): http://europepmc.org/abstract/med/23657518.
  62. Araújo A. "[Cancer and deep venous thrombosis: the purpose of the CATCH clinical trial].". (2013): http://europepmc.org/abstract/med/23809736.
  63. Guedes, Joana G; Veiga, Isabel; Rocha, Patrícia; Pinto, Pedro; Pinto, Carla; Pinheiro, Manuela; Peixoto, Ana; et al. "High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer". (2013): http://www.biomedcentral.com/1471-2407/13/169.
  64. Reis, R. M.; Mello, Ramon Andrade de; Araújo, António; Hespanhol, Venceslau. "Loci identified through genome-wide association studies and lung cancer risk : is there anything more?". (2013): http://hdl.handle.net/1822/24802.
    10.1590/S1516-31802013000100026
  65. De Mello, Ramon Andrade; Araújo, António. "Anaplastic lymphoma kinase gene rearrangement and non-small cell lung cancer management: a step forward in personalized therapy". (2013): http://www.revistas.usp.br/clinics/article/view/76854.
    10.1590/clin.v68i5.76854
  66. Luis, M.; Tavares, A.; Carvalho, L.S.; Lara-Santos, L.; Araújo, A.; de Mello, R.A.. "Personalizing therapies for gastric cancer: Molecular mechanisms and novel targeted therapies". World Journal of Gastroenterology 19 38 (2013): 6383-6397. http://www.scopus.com/inward/record.url?eid=2-s2.0-84885603623&partnerID=MN8TOARS.
    10.3748/wjg.v19.i38.6383
  67. de Mello, R.A.; Marques, A.M.; Araújo, A.. "Epidermal growth factor receptor and metastatic colorectal cancer: Insights into target therapies". World Journal of Gastroenterology 19 38 (2013): 6315-6318. http://www.scopus.com/inward/record.url?eid=2-s2.0-84885588302&partnerID=MN8TOARS.
    10.3748/wjg.v19.i38.6315
  68. Hespanhol, V.; Parente, B.; Araújo, A.; Cunha, J.; Fernandes, A.; Figueiredo, M.M.; Neveda, R.; et al. "Lung cancer in Northern Portugal: A hospital-based study | Cancro do pulmão no norte de Portugal: um estudo de base hospitalar". Revista Portuguesa de Pneumologia (2013): http://www.scopus.com/inward/record.url?eid=2-s2.0-84884991629&partnerID=MN8TOARS.
    10.1016/j.rppneu.2013.05.005
  69. de Mello, R.A.; Marques, A.M.; Araújo, A.. "HER2 therapies and gastric cancer: A step forward". World Journal of Gastroenterology 19 37 (2013): 6165-6169. http://www.scopus.com/inward/record.url?eid=2-s2.0-84885578812&partnerID=MN8TOARS.
    10.3748/wjg.v19.i37.6165
  70. Guedes, J.G.; Veiga, I.; Rocha, P.; Pinto, P.; Pinto, C.; Pinheiro, M.; Peixoto, A.; et al. "High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer". BMC Cancer 13 (2013): http://www.scopus.com/inward/record.url?eid=2-s2.0-84875483113&partnerID=MN8TOARS.
    10.1186/1471-2407-13-169
  71. Araujo, Antonio. "Cancer and Deep Venous Thrombosis: the Purpose of the CATCH Clinical Trial". Acta Médica Portuguesa (2013): https://publons.com/wos-op/publon/20962674/.
  72. Hespanhol, V.; Parente, B.; Araujo, A.; Cunha, J.; Fernandes, A.; Figueiredo, M. M.; Neveda, R.; et al. "Lung cancer in Northern Portugal: A hospital-based study". Revista Portuguesa de Pneumologia (2013): https://publons.com/wos-op/publon/61788416/.
  73. De Mello RA; Araújo A. "Epidermal growth factor receptor mutation frequency and non-small cell lung cancer management: implication for treatment choices.". (2012): http://europepmc.org/abstract/med/23184216.
  74. Catarino R; Coelho A; Nogueira A; Araújo A; Gomes M; Lopes C; Medeiros R. "Cyclin D1 polymorphism in non-small cell lung cancer in a Portuguese population.". (2012): http://europepmc.org/abstract/med/23396251.
    10.3233/CBM-130294
  75. De Mello, Ramon Andrade; Araújo, António. "Epidermal growth factor receptor mutation frequency and non-small cell lung cancer management: implication for treatment choices". (2012): http://www.revistas.usp.br/clinics/article/view/47962.
    10.6061/clinics/2012(11)22
  76. Araújo, António. "Personalizing medicine – strategies for implementing the evaluation of ALK rearrangement in non-small-cell lung cancer in Portugal". (2012):
    10.1016/j.rppnen.2012.06.004
  77. Catarino, R.; Coelho, A.; Araújo, A.; Gomes, M.; Nogueira, A.; Lopes, C.; Medeiros, R.. "Circulating DNA: Diagnostic tool and predictive marker for overall survival of NSCLC patients". PLoS ONE 7 6 (2012): http://www.scopus.com/inward/record.url?eid=2-s2.0-84862177008&partnerID=MN8TOARS.
    10.1371/journal.pone.0038559
  78. Estevinho, F.; Soares, M.; Azevedo, I.; Queiroga, H.; Parente, B.; Brito, U.; Teixeira, E.; Sotto-Mayor, R.; Araújo, A.. "Bevacizumab for the treatment of nonsquamous non-small-cell lung cancer in Portugal: A retrospective, multicenter study". Cancer Management and Research 4 1 (2012): 91-97. http://www.scopus.com/inward/record.url?eid=2-s2.0-84859527964&partnerID=MN8TOARS.
    10.2147/CMAR.S29672
  79. Joaquim, A.; Custódio, S.; Pimentel, F.L.; Fidalgo Matos, J.; Peixoto, V.; Faria, A.L.; Espiga MacEdo, J.; et al. "Bacillary prostatitis after intravesical immunotherapy: A rare adverse effect". Case Reports in Oncology 5 1 (2012): 80-83. http://www.scopus.com/inward/record.url?eid=2-s2.0-84860741035&partnerID=MN8TOARS.
    10.1159/000336445
  80. Custódio, S.; Joaquim, A.; Peixoto, V.; MacEdo, J.E.; Faria, A.L.; MacIas, E.; Rego, S.; Araújo, A.. "Metastatic renal cell carcinoma: The importance of immunohistochemistry in differential diagnosis". Case Reports in Oncology 5 1 (2012): 30-34. http://www.scopus.com/inward/record.url?eid=2-s2.0-84860774735&partnerID=MN8TOARS.
    10.1159/000335683
  81. Araújo, A.; Coelho, A.; de Mello, R.A.; Azevedo, I.; Soares, M.; Queiroga, H.; Teixeira, E.; Parente, B.; Barata, F.. "Personalizing medicine - Strategies for implementing the evaluation of anaplastic lymphoma kinase rearrangement in non-small-cell lung cancer in Portugal | Personalizando a medicina - Estratégias para implementar a avaliação do rearranjo do 'anaplastic lymphoma kinase' no carcinoma do pulmão de não pequenas células em Portugal". Revista Portuguesa de Pneumologia 18 5 (2012): 244-246. http://www.scopus.com/inward/record.url?eid=2-s2.0-84869880978&partnerID=MN8TOARS.
    10.1016/j.rppneu.2012.04.011
  82. Gomes, M.; Coelho, A.; Araújo, A.; Teixeira, A.L.; Catarino, R.; Medeiros, R.. "Influence of functional genetic polymorphism (-590C/T) in non-small cell lung cancer (NSCLC) development: The paradoxal role of IL-4". Gene 504 1 (2012): 111-115. http://www.scopus.com/inward/record.url?eid=2-s2.0-84862309386&partnerID=MN8TOARS.
    10.1016/j.gene.2012.05.008
  83. de Mello, R.A.; Pires, F.S.; Marques, D.S.; Oliveira, J.; Rodrigues, A.; Soares, M.; Azevedo, I.; et al. "EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study". Tumor Biology (2012): 1-8. http://www.scopus.com/inward/record.url?eid=2-s2.0-84864133421&partnerID=MN8TOARS.
    10.1007/s13277-012-0465-5
  84. Araújo, António. "Bevacizumab for the treatment of nonsquamous non-small-cell lung cancer in Portugal: a retrospective, multicenter study". (2012):
    10.2147/cmar.s29672
  85. de Mello RA; Marques DS; Medeiros R; Araújo AM. "Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies.". World journal of clinical oncology (2011): http://europepmc.org/abstract/med/22087435.
    10.5306/wjco.v2.i11.367
  86. Pinto, P.; Rocha, P.; Veiga, I.; Guedes, J.; Pinheiro, M.; Peixoto, A.; Pinto, C.; et al. "Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer". Cancer Genetics 204 8 (2011): 439-446. http://www.scopus.com/inward/record.url?eid=2-s2.0-84856399968&partnerID=MN8TOARS.
    10.1016/j.cancergen.2011.07.003
  87. Pantarotto, M.; Lombo, L.; Pereira, H.; Araújo, A.. "Cutaneous metastasis as the initial manifestation of lung adenocarcinoma | Metástase cutânea como primeira manifestação de adenocarcinoma pulmonar". Jornal Brasileiro de Pneumologia 37 4 (2011): 556-559. http://www.scopus.com/inward/record.url?eid=2-s2.0-80052736927&partnerID=MN8TOARS.
    10.1590/S1806-37132011000400018
  88. Teixeira, A.L.; Araújo, A.; Coelho, A.; Ribeiro, R.; Gomes, M.; Pereira, C.; Medeiros, R.. "Influence of TGFB1+869T>C functional polymorphism in non-small cell lung cancer (NSCLC) risk". Journal of Cancer Research and Clinical Oncology 137 3 (2011): 435-439. http://www.scopus.com/inward/record.url?eid=2-s2.0-79954437963&partnerID=MN8TOARS.
    10.1007/s00432-010-0896-6
  89. Araújo, António. "1137 POSTER Is MMP-9 Q279R a Possible Marker of Prognostic in Non Small Cell Lung Cancer?". (2011):
    10.1016/s0959-8049(11)70780-8
  90. Araújo, António. "Topotecan in Second-Line Treatment of Small-Cell Lung Cancer – How it Works in Our Daily Clinical Practice?". (2010):
    10.2174/157488610790936123
  91. Araujo, A. M.. "Pemetrexed Plus Bevacizumab for Second-Line Therapy of Non-Small-Cell Lung Cancer: The Importance of Patient Selection". Journal of Clinical Oncology 28 8 (2010): e131-e131. http://dx.doi.org/10.1200/JCO.2009.26.7351.
    10.1200/jco.2009.26.7351
  92. Nogueira, A.; Catarino, R.; Coelho, A.; Araújo, A.; Gomes, M.; Medeiros, R.. "Influence of DNA repair RAD51 gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy". Cancer Chemotherapy and Pharmacology 66 3 (2010): 501-506. http://www.scopus.com/inward/record.url?eid=2-s2.0-77954680606&partnerID=MN8TOARS.
    10.1007/s00280-009-1187-2
  93. Catarino, R.; Araujo, A.; Coelho, A.; Gomes, M.; Nogueira, A.; Lopes, C.; Medeiros, R. M.. "Prognostic Significance of Telomerase Polymorphism in Non-Small Cell Lung Cancer". Clinical Cancer Research 16 14 (2010): 3706-3712. http://dx.doi.org/10.1158/1078-0432.CCR-09-3030.
    10.1158/1078-0432.ccr-09-3030
  94. Catarino, R.; Araújo, A.; Coelho, A.; Gomes, M.; Nogueira, A.; Lopes, C.; Medeiros, R.M.. "Prognostic significance of telomerase polymorphism in non-small cell lung cancer". Clinical Cancer Research 16 14 (2010): 3706-3712. http://www.scopus.com/inward/record.url?eid=2-s2.0-77954700718&partnerID=MN8TOARS.
    10.1158/1078-0432.CCR-09-3030
  95. Faria, A.L.L.M.; BravO., E.M.; Rocha, M.A.S.S.; Rocha, I.M.A.; CoelhO., A.L.P.; Araújo, A.M.F.. "Topotecan in second-line treatment of Small-cell lung cancer - How it works in our daily clinical practice?". Current Drug Safety 5 2 (2010): 114-117. http://www.scopus.com/inward/record.url?eid=2-s2.0-77950793990&partnerID=MN8TOARS.
  96. Araujo, A.M.. "Pemetrexed plus bevacizumab for second-line therapy of non-small-cell lung cancer: The importance of patient selection". Journal of Clinical Oncology 28 8 (2010): http://www.scopus.com/inward/record.url?eid=2-s2.0-77950503737&partnerID=MN8TOARS.
    10.1200/JCO.2009.26.7351
  97. Bartminski W. "Araujo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer. Rev Port Pneumol 2008; 14(6):803-827.". (2009): http://europepmc.org/abstract/med/19526635.
  98. Araújo A; Barata F; Barroso S; Cortes P; Damasceno M; Parreira A; Espírito Santo J; Teixeira E; Pereira R. "[Cost of cancer care in Portugal].". (2009): http://europepmc.org/abstract/med/19944035.
  99. Pereira, A.; Machado, P.; Araújo, A.; Coelho, A.; Teixeira, A.L.; Medeiros, R.. "9059 8473T>C COX-2 polymorphism and susceptibility for lung cancer: a strategy for individualised chemoprevention". European Journal of Cancer Supplements 7 2 (2009): 523-523. http://dx.doi.org/10.1016/S1359-6349(09)71772-0.
    10.1016/s1359-6349(09)71772-0
  100. Araújo, António. "9060 Cyclin D1 and Non-Small cell lung cancer – a role of CCND1 gene variants in lung carcinogenesis". (2009):
    10.1016/s1359-6349(09)71773-2
  101. Araújo, António. "Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803–827". (2009):
    10.1016/s2173-5115(09)70133-2
  102. Araújo, António. "1094 Influence of TGFB1+869T>c polymorphism in non-small cell lung cancer (NSCLC) risk". (2009):
    10.1016/s1359-6349(09)70387-8
  103. Araújo, António. "1098 Influence of IL-4 -590C/T polymorphism in Non-Small Cell Lung Cancer (NSCLC) susceptibility". (2009):
    10.1016/s1359-6349(09)70391-x
  104. Araújo, António. "Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803–827". (2009):
    10.1016/s2173-5115(09)70132-0
  105. Araújo, António. "9132 The importance of haematological toxicity on outcomes of small-cell lung cancer patients". (2009):
    10.1016/s1359-6349(09)71845-2
  106. Coelho A; Pereira D; Nogal A; Pinto D; Catarino R; Araújo A; Medeiros R. "CXCL12 chemokine genotypes as predictive biomarkers of ovarian cancer outcome.". Molecular medicine reports (2009): http://europepmc.org/abstract/med/21475798.
    10.3892/mmr_00000069
  107. Araújo, A.; Barata, F.; Barroso, S.; Cortes, P.; Damasceno, M.; Parreira, A.; Espírito Santo, J.; Teixeira, E.; Pereira, R.. "Cost of cancer care in Portugal | Custo do tratamento do cancro em Portugal". Acta Medica Portuguesa 22 5 (2009): 525-536. http://www.scopus.com/inward/record.url?eid=2-s2.0-77149180115&partnerID=MN8TOARS.
  108. Coelho, A.; Pereira, D.; Nogal, A.; Pinto, D.; Catarino, R.; Araújo, A.; Medeiros, R.. "CXCL12 chemokine genotypes as predictive biomarkers of ovarian cancer outcome". Molecular Medicine Reports 2 1 (2009): 103-106. http://www.scopus.com/inward/record.url?eid=2-s2.0-69249152606&partnerID=MN8TOARS.
    10.3892/mmr-00000069
  109. Araújo, A.M.F.; Mendez, J.C.; Coelho, A.L.; Sousa, B.; Barata, F.; Fiqueiredo, A.; Amaro, T.; Azevedo, I.; Soares, M.. "Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer". Cancer Investigation 27 4 (2009): 391-396. http://www.scopus.com/inward/record.url?eid=2-s2.0-65249102331&partnerID=MN8TOARS.
    10.1080/07357900802232756
  110. Araujo, Antonio; Barata, Fernando; Barroso, Sergio; Cortes, Paulo; Damasceno, Margarida; Parreira, Antonio; Santo, Jorge Espirito; Teixeira, Encarnacao; Pereira, Ricardo. "COST OF CANCER CARE IN PORTUGAL". Acta Médica Portuguesa (2009): https://publons.com/wos-op/publon/20962709/.
  111. Araújo A; Soares M; Azevedo I. "Erlotinib in second-line therapy for non-small cell lung cancer - A clinical case.". Revista portuguesa de pneumologia (2008): http://europepmc.org/abstract/med/25967682.
    10.1016/s0873-2159(15)30317-2
  112. Araújo A; Barata F; Parente B; Rego S; Teixeira E; Melo M; Queiroga H; et al. "Pemetrexed in second line treatment of non-small cell lung cancer - The portuguese experience.". Revista portuguesa de pneumologia (2008): http://europepmc.org/abstract/med/25967568.
    10.1016/s0873-2159(15)30310-x
  113. Araújo A; Parente B; Sotto-Mayor R; Teixeira E; Almodôvar T; Barata F; Queiroga H; et al. "An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer.". (2008): http://europepmc.org/abstract/med/19023496.
  114. Lima, A.; Araujo, A.; Coelho, A.; Ribeiro, R.; Seabra, V.; Medeiros, R.. "Thymidylate synthase genotypes as a prognostic factor in non-small cell lung cancer patients". European Journal of Cancer Supplements 6 9 (2008): 102-102. http://dx.doi.org/10.1016/S1359-6349(08)71567-2.
    10.1016/s1359-6349(08)71567-2
  115. Araújo, A.; Parente, B.; Sotto-Mayor, R.; Teixeira, E.; Almodôvar, T.; Barata, F.; Queiroga, H.; et al. "An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer | Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células". Revista Portuguesa de Pneumologia 14 6 (2008): 803-827. http://www.scopus.com/inward/record.url?eid=2-s2.0-60849118404&partnerID=MN8TOARS.
  116. Coelho, A.; Catarino, R. J.; Gomes, M.; Nogal, A.; Araujo, A.; Medeiros, R.. "-592 IL10 POLYMORPHISM AS A PROGNOSTIC FACTOR IN LUNG CANCER PATIENTS". Annals of Oncology (2008): https://publons.com/wos-op/publon/4932531/.
  117. Araujo, A.; Parente, B.; Sotto-Mayor, R.; Teixeira, E.; Almodovar, T.; Barata, F.; Queiroga, H.; et al. "An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer". Revista Portuguesa de Pneumologia (2008): https://publons.com/wos-op/publon/20962704/.
    10.1016/S2173-5115(08)70309-9
  118. Macedo JE; Abreu I; Marques M; Henrique R; Araújo A. "A clinical case of Castleman's disease.". (2007): http://europepmc.org/abstract/med/17410052.
  119. Ribeiro R; Araújo A; Lopes C; Medeiros R. "Immunoinflammatory mechanisms in lung cancer development: is leptin a mediator?". (2007): http://europepmc.org/abstract/med/17410023.
  120. Araújo A; Ribeiro R; Azevedo I; Coelho A; Soares M; Sousa B; Pinto D; et al. "Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature.". (2007): http://europepmc.org/abstract/med/17296816.
  121. Macedo JE; Machado M; Araújo A; Angélico V; Lopes JM. "Orbital metastasis as a rare form of clinical presentation of non-small cell lung cancer.". (2007): http://europepmc.org/abstract/med/17410035.
  122. Parente B; Queiroga H; Teixeira E; Sotto-Mayor R; Barata F; Sousa A; Melo MJ; et al. "[Epidemiological study of lung cancer in Portugal (2000/2002)].". (2007): http://europepmc.org/abstract/med/17571453.
  123. Faria, Ana Luísa L.; Araújo, António; Soares, Marta; Azevedo, Isabel; Leal da Silva, José. "P1-217: Retrospective study about using topotecan in second-line treatment of small-cell lung cancer. Experience of a single institution, from 2002 to 2006". (2007): http://dx.doi.org/10.1097/01.jto.0000284315.81586.51.
    10.1097/01.jto.0000284315.81586.51
  124. Sousa B; Araújo A; Amaro T; Azevedo I; Soares M; Sousa O. "Malignant thymomas--the experience of the Portuguese Oncological Institute, Porto, and literature review.". Revista portuguesa de pneumologia (2007): http://europepmc.org/abstract/med/17898913.
    10.1016/s0873-2159(15)30364-0
  125. Macedo, Joana Espiga; Machado, Manuela; Araújo, António; Angélico, Vítor; Lopes, José M.. "Orbital Metastasis as a Rare Form of Clinical Presentation of Non-small Cell Lung Cancer". (2007): http://dx.doi.org/10.1097/jto.0b013e31802c0036.
    10.1097/jto.0b013e31802c0036
  126. Araújo, António. "6536 POSTER CYP3A5 polymorphism and NSCLC – a role for genetic variation as a protective factor in lung cancer susceptibility". (2007):
    10.1016/s1359-6349(07)71364-2
  127. Araújo, António. "6541 POSTER Genetic polymorphism of the epidermal growth factor gene – value for the treatment of non-small cell lung cancer (NSCLC)". (2007):
    10.1016/s1359-6349(07)71369-1
  128. Douillard, J.Y.; Coudert, B.; Gridelli, C.; Mohn-Staudner, A.; Salzberg, B.; Almodovar, T.; Araujo, A.; et al. "6507 ORAL Phase III study of IV vinflunine (VFL) versus IV docetaxel (DTX) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen". European Journal of Cancer Supplements 5 4 (2007): 358-358. http://dx.doi.org/10.1016/S1359-6349(07)71335-6.
    10.1016/s1359-6349(07)71335-6
  129. Sousa, B.; Araújo, A.; Amaro, T.; Azevedo, I.; Soares, M.; Sousa, O.. "Malignant thymomas - The experience of the Portuguese Oncological Institute, Porto, and literature review | Timomas malignos - A experiência do IPO do Porto e revisão da literatura". Revista Portuguesa de Pneumologia 13 4 (2007): 553-585. http://www.scopus.com/inward/record.url?eid=2-s2.0-34548617844&partnerID=MN8TOARS.
  130. Parente, B.; Queiroga, H.; Teixeira, E.; Sotto-Mayor, R.; Barata, F.; Sousa, A.; Melo, M.J.; et al. "Epidemiological study of lung cancer in Portugal (2000/2002) | Estudo epidemiológico do cancro do pulmão em Portugal nos anos de 2000/2002". Revista Portuguesa de Pneumologia 13 2 (2007): 255-265. http://www.scopus.com/inward/record.url?eid=2-s2.0-34249750529&partnerID=MN8TOARS.
  131. Macedo, J.E.; Abreu, I.; Marques, M.; Henrique, R.; Araújo, A.. "A clinical case of Castleman's disease". Journal of Thoracic Oncology 2 3 (2007): 259-260. http://www.scopus.com/inward/record.url?eid=2-s2.0-34247141938&partnerID=MN8TOARS.
    10.1097/JTO.0b013e318031b633
  132. Macedo, J.E.; Machado, M.; Araújo, A.; Angélico, V.; Lopes, J.M.. "Orbital metastasis as a rare form of clinical presentation of non-small cell lung cancer". Journal of Thoracic Oncology 2 2 (2007): 166-167. http://www.scopus.com/inward/record.url?eid=2-s2.0-34247109577&partnerID=MN8TOARS.
    10.1097/JTO.0b013e31802c0036
  133. Araújo, A.; Ribeiro, R.; Azevedo, I.; Coelho, A.; Soares, M.; Sousa, B.; Pinto, D.; et al. "Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer - A review of the literature". Oncologist 12 2 (2007): 201-210. http://www.scopus.com/inward/record.url?eid=2-s2.0-33847056277&partnerID=MN8TOARS.
    10.1634/theoncologist.12-2-201
  134. Ribeiro, R.; Araújo, A.; Lopes, C.; Medeiros, R.. "Immunoinflammatory mechanisms in lung cancer development: Is leptin a mediator?". Journal of Thoracic Oncology 2 2 (2007): 105-108. http://www.scopus.com/inward/record.url?eid=2-s2.0-34247104585&partnerID=MN8TOARS.
  135. Ribeiro, Ricardo; Araújo, António; Lopes, Carlos; Medeiros, Rui. "Immunoinflammatory Mechanisms in Lung Cancer Development: Is Leptin a Mediator?". (2007): http://dx.doi.org/10.1016/s1556-0864(15)30035-6.
    10.1016/s1556-0864(15)30035-6
  136. Macedo A; Araújo A; Melo FC; Nunes G; Cantinho G; Amorin I. "[Cost-effectiveness of samarium-153-EDTMP for the treatment of pain due to multiple bone metastases in hormone-refractory prostate cancer versus conventional pain therapy, in Portugal].". (2006): http://europepmc.org/abstract/med/17376329.
  137. Ribeiro, R.; Araújo, A.P.; Coelho, A.; Catarino, R.; Pinto, D.; Araújo, A.; Calçada, C.; Lopes, C.; Medeiros, R.. "A functional polymorphism in the promoter region of leptin gene increases susceptibility for non-small cell lung cancer". European Journal of Cancer 42 8 (2006): 1188-1193. http://www.scopus.com/inward/record.url?eid=2-s2.0-33646414773&partnerID=MN8TOARS.
    10.1016/j.ejca.2006.02.004
  138. Araujo, A.; Teixeira, M.; Figueiredo, A.; Correia, J.; Melo, M.; Parente, B.; Bernardo, M.; Queiroga, H.; Barata, F.. "P-447 Treatment of non-small-cell lung cancer with gefitinib (IRESSA)in a compassionate-use program: The Portuguese experience". Lung Cancer 49 (2005): S233-S234. http://dx.doi.org/10.1016/S0169-5002(05)80940-7.
    10.1016/s0169-5002(05)80940-7
  139. Barata, F.; Parente, B.; Teixeira, E.; Nogueira, F.; Fernandes, A.; Cunha, J.; Araújo, A.; et al. "PD-065 Duration of chemotherapy in non-small-cell lung cancer: Multicenter, randomized, prospective clinical trial comparing 4 vs 6 cycles of carboplatin and gemcitabine. (Portuguese Lung Cancer Study Group 03/03)". Lung Cancer 49 (2005): S85-S85. http://dx.doi.org/10.1016/S0169-5002(05)80398-8.
    10.1016/s0169-5002(05)80398-8
  140. Méndez, J.C.; Araújo, A.M.; Escobar, C.; Guilherme, M.; Lopes, C.; Ferreira, E.P.. "Solid pseudopapillary pancreas tumor: Case report | Tumor pseudopapilar sólido do pâncreas: A propósito de um caso clínico". Arquivos de Medicina 17 1-3 (2003): 96-99. http://www.scopus.com/inward/record.url?eid=2-s2.0-0041926667&partnerID=MN8TOARS.
  141. Araújo, António. "809 Primary orbital and adnexal non-Hodgkin lymphoma (POAL): A single centre study of 20 cases". (1995):
    10.1016/0959-8049(95)96058-l

Outros

Outra produção
  1. Epidermal growth factor receptor mutation frequency and non-small cell lung cancer management: implication for treatment choices. 2012. De Mello, Ramon Andrade; Araújo, António. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488998.
Atividades

Orientação

Título / Tema
Papel desempenhado 		Curso (Tipo)
Instituição / Organização
2022 - 2022 Impacto da pandemia COVID-19 no diagnóstico e tratamento do cancro da mama: a experiência de um hospital terciário português
Orientador
 Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2022 - 2022 Cancro da mama triplo negativo: revisão de novas abordagens terapêuticas
Orientador
 Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2022 - 2022 Programas de Rastreio Oncológico em Portugal
Orientador
 Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2021 - 2021 The Impact of COVID-19 on Cancer Therapy
Orientador
 Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2021 - 2021 "Radiações do quotidiano e da medicina na carcinogénese "
Orientador
 Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2021 - 2021 RET rearrangements: targeted therapy in lung cancer
Orientador
 Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2020 - 2020 O papel da imunoterapia no tratamento do cancro colo-retal
Orientador
 Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2019 - 2019 Revisitar a importância do ROS1 no tratamento do carcinoma do pulmão
Orientador
 Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2019 - 2019 Thrombophilia as a risk factor for venous thromboembolism is patients with cancer - should cancer patients be screened for throbophilia?
Orientador
 Ciências Médicas (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2018 - 2018 Emese induzida pela quimioterapia - ainda um problema?
Orientador
 Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2018 - 2018 Estudo dos níveis circulantes e exossomais de mRNA de VEGF e Ang-2 em Cancro do Pulmão
Coorientador
 Bioquímica (Mestrado)
Universidade do Porto Faculdade de Ciências, Portugal
2017 - 2017 Immunotherapy in colorectal cancer: is there a role?
Orientador
 Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017 - 2017 Qualidade de vida e doença oncológica-Validação de dois questionários de avaliação da qualidade de vida do doente oncológico
Orientador
 Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017 - 2017 Mecanismos de Resistência aos Inibidores PD1/PDL1
Orientador
 Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017 - 2017 Papel das biopsias líquidas no cancro esofágico, gástrico, pancreático e colo-retal
Orientador
 Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017 - 2017 O papel da actividade física e do exercício no tratamento do cancro do pulmão
Orientador
 Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2016 - 2016 Relevance of circulating markers of inflammation and metastization in the NSCLC landscape. The use of Lymphoblastoid Cell Lines from patients
Orientador
 Oncologia (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2016 - 2016 Impacto da infeção pelo vírus da imunodeficiência humana no cancro do pulmão de não pequenas células
Orientador
 Medicina (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2014 - 2014 Efeito da acupunctura nas células NK em doentes com cancro da mama submetidas a quimioterapia neoadjuvante e adjuvante - Estudo prospetivo, randomizado e controlado
Orientador
 Medicina Tradicional Chinesa (Mestrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Organização de evento

Nome do evento
Tipo de evento (Tipo de participação) 		Instituição / Organização
2015/11/05 - Atual Post-Graduate Course in Oncology for General Practitioners and Young Oncologists - OncoGP (2015/11/05)
Outro (Presidente da Comissão Organizadora)
 Centro Hospitalar Universitário do Porto EPE, Portugal

Curso / Disciplina lecionado

Disciplina Curso (Tipo) Instituição / Organização
2020/09/01 - Atual Especialidades Médicas II Mestrado Integrado em Medicina Dentária (Mestrado integrado) Universidade do Porto Faculdade de Medicina Dentária, Portugal
2015/09/01 - Atual Oncologia Clínica Mestrado Integrado em Medicina (Mestrado integrado) Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2013/09/01 - Atual Medicina II e Especialidades Médicas Mestrado Integrado em Medicina (Mestrado integrado) Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Membro de associação

Nome da associação Tipo de participação
2021/02/12 - Atual REDICAP - Red IberoAmericana de Cancer de Pulmón Membro Fundador
2019/01/01 - Atual Registo Oncológico Nacional Membro da Comissão Científica
2013/01/01 - Atual Conselho Nacional para a Oncologia Membro
2017/01/01 - 2022/12/31 Ordem dos Médicos Presidente do Conselho Regional do Norte
2006/01/01 - 2012/12/31 Grupo de Estudos do Cancro do Pulmão Membro da Direcção

Membro de comissão

Descrição da atividade
Tipo de participação 		Instituição / Organização
2019/01/01 - Atual Comité de Educação
Membro
 International Association for the Study of Lung Cancer, Estados Unidos
2015/01/01 - 2019/12/31 Comité de Ética
Membro
 International Association for the Study of Lung Cancer, Estados Unidos
Distinções

Outra distinção

2024 Profissional do ano
Rotary Club Porto-Foz, Portugal
2023 Distinção de Mérito Ricardo Jorge
Câmara Municipal do Porto, Portugal
2022 Medalha de Mérito do Munícipio do Porto - Grau Ouro
Câmara Municipal do Porto, Portugal